COVID-19 and liver injury: where do we stand?

Papadopoulos, Nikolaos; Vasileiadi, Sofia; Deutsch, Melanie

doi:10.20524/aog.2020.0522

Cited by 16 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatic enzyme derangements are considered as the most common extrapulmonary findings in the context of COVID-19[ 92 ]. The incidence of an abnormal liver function test in this context varies from 1% to 76% in the published literature[ 93 - 96 ].…”

Section: Liver-related Manifestations In Patients With Covid-19mentioning

confidence: 99%

COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges

Sivandzadeh¹,

Askari²,

Safarpour³

et al. 2021

WJCC

View full text Add to dashboard Cite

It is hypothesized that liver impairment caused by coronavirus disease 2019 (COVID-19) infection might play a central role in severe clinical presentations. Liver injury is closely associated with severe disease and, even with antiviral drugs, have a poor prognosis in COVID-19 patients. In addition to the common hepatobiliary disorders caused by COVID-19, patients with pre-existing liver diseases demand special considerations during the current pandemic. Thus, it is vital that upon clinical presentation, patients with concurrent pre-existing liver disease associated with metabolic dysfunction and COVID-19 be managed properly to prevent liver failure. Careful monitoring and early detection of liver damage through biomarkers after hospitalization for COVID-19 is underscored in all cases, particularly in those with pre-existing metabolic liver injury. The purpose of this study was to determine most recent evidence regarding causality, potential risk factors, and challenges, therapeutic options, and management of COVID-19 infection in vulnerable patients with pre-existing liver injury. This review aims to highlight the current frontier of COVID-19 infection and liver injury and the direction of liver injury in these patients.

show abstract

Section: Liver-related Manifestations In Patients With Covid-19mentioning

confidence: 99%

COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges

Sivandzadeh¹,

Askari²,

Safarpour³

et al. 2021

WJCC

View full text Add to dashboard Cite

show abstract

“…However, during illness, one of the most important points to consider is the use of medications that can cause DILI in COVID-19 patients. Also, more careful monitoring of liver enzymes in serum is required, especially in hospitalized patients or patients with liver disease (Papadopoulos et al 2020 ). Current knowledge about contributing factors such as liver failure or concomitant drug use remains largely unknown.…”

Section: Liver In Pathogenesis Of Covid-19mentioning

confidence: 99%

Revealed pathophysiological mechanisms of crosslinking interaction of affected vital organs in COVID-19

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 is one of the main serious challenges of human societies, which emerged in December 2019 from China and quickly extends to all parts of the world. The virus was previously believed to only affect the lungs and respiratory system, but subsequent research has revealed that it affects a variety of organs. For this reason, this disease is known as a multiorgan disease. Current article aimed to highlight latest information and updates about molecular studies regarding pathogenesis of SARS-CoV-2 in kidney, liver, and cardiovascular and respiratory systems, as well as the mechanisms of interaction of these organs with each other to cause clinical manifestations in patients.

show abstract

“…Elevation in GGT levels was more noticeable in severe cases, while ALP levels usually remained normal in both mild and severe cases[ 35 ]. Variable and inconsistent degrees of LFTs abnormalities, ranging from 3.75% to more than 50% of all patients, have been described[ 5 , 25 , 33 , 36 ]. A meta-analysis found a pooled incidence of elevated liver enzymes by 23.1%[ 37 ].…”

Section: Prevalence and Consequences Of Covid-19-associated Liver Injurymentioning

confidence: 99%

“…Underlying CLD in patients with COVID-19 have been reported in several studies and ranged from 2% to 11%[ 30 , 36 , 64 ], up to 19% in one study[ 65 ]. Pooled prevalence of pre-existing CLD in one meta-analysis was 3%[ 66 ], which was comparable to that of another meta-analysis (3.6%)[ 5 ].…”

Section: Pre-existing Liver Disease In Covid-19-associated Liver Injurymentioning

confidence: 99%

Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units

Omar

Kaddoura

Orabi

et al. 2021

WJH

View full text Add to dashboard Cite

Emerging worldwide data have been suggesting that coronavirus disease 2019 (COVID-19) pandemic consequences are not limited to the respiratory and cardiovascular systems but encompass adverse gastrointestinal manifestations including acute liver injury as well. Severe cases of liver injury associated with higher fatality rates were observed in critically ill patients with COVID-19. Intensive care units (ICU) have been the center of disposition of severe cases of COVID-19. This review discusses the pathogenesis of acute liver injury in ICU patients with COVID-19, and analyzes its prevalence, consequences, possible drug-induced liver injury, and the impact of the pandemic on liver diseases and transplantation programs.

show abstract

COVID-19 and liver injury: where do we stand?

Cited by 16 publications

References 32 publications

COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges

COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges

Revealed pathophysiological mechanisms of crosslinking interaction of affected vital organs in COVID-19

Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units

Contact Info

Product

Resources

About